The invention relates to a compound selected from those of general formula (I): ##STR1## in which R, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification, an optical isomer, and an addition salt thereof with a pharmaceutically-acceptable base. Medicinal product which is useful in the treatment of disorders linked to abnormal melatonin activity.
该发明涉及一种化合物,选择自以下通式(I)的化合物:##STR1## 其中R,R.sub.1,R.sub.2和R.sub.3如规范中所定义,其光学异构体和与药学上可接受的碱形成的加合物。该药物产品对治疗与异常
褪黑激素活动相关的疾病有用。